HRP20191366T4 - Injekcijski pripravak - Google Patents
Injekcijski pripravak Download PDFInfo
- Publication number
- HRP20191366T4 HRP20191366T4 HRP20191366TT HRP20191366T HRP20191366T4 HR P20191366 T4 HRP20191366 T4 HR P20191366T4 HR P20191366T T HRP20191366T T HR P20191366TT HR P20191366 T HRP20191366 T HR P20191366T HR P20191366 T4 HRP20191366 T4 HR P20191366T4
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- quinolin
- benzo
- butoxy
- preparation according
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 39
- 150000003839 salts Chemical class 0.000 claims 43
- 238000002347 injection Methods 0.000 claims 18
- 239000007924 injection Substances 0.000 claims 18
- 239000000375 suspending agent Substances 0.000 claims 18
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 17
- 229960004372 aripiprazole Drugs 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 13
- 239000007788 liquid Substances 0.000 claims 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 10
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 239000011164 primary particle Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 229940071643 prefilled syringe Drugs 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 239000000084 colloidal system Substances 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000004683 dihydrates Chemical group 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000011163 secondary particle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636938P | 2012-04-23 | 2012-04-23 | |
| US201361792089P | 2013-03-15 | 2013-03-15 | |
| EP13728542.5A EP2841054B2 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
| PCT/JP2013/062683 WO2013162048A1 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191366T1 HRP20191366T1 (hr) | 2019-12-27 |
| HRP20191366T4 true HRP20191366T4 (hr) | 2022-08-19 |
Family
ID=48614096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191366TT HRP20191366T4 (hr) | 2012-04-23 | 2013-04-23 | Injekcijski pripravak |
Country Status (31)
| Country | Link |
|---|---|
| US (9) | US20150093442A1 (enExample) |
| EP (2) | EP3539534A1 (enExample) |
| JP (7) | JP6234996B2 (enExample) |
| KR (4) | KR102138852B1 (enExample) |
| CN (3) | CN104470499B (enExample) |
| AR (1) | AR090776A1 (enExample) |
| AU (6) | AU2013253374B2 (enExample) |
| BR (1) | BR112014026307B1 (enExample) |
| CA (2) | CA3120297A1 (enExample) |
| CO (1) | CO7151500A2 (enExample) |
| CY (1) | CY1122252T1 (enExample) |
| DK (1) | DK2841054T4 (enExample) |
| EA (1) | EA026619B1 (enExample) |
| ES (1) | ES2743706T5 (enExample) |
| HR (1) | HRP20191366T4 (enExample) |
| HU (1) | HUE045979T2 (enExample) |
| IL (1) | IL235299B (enExample) |
| JO (2) | JOP20200109A1 (enExample) |
| LT (1) | LT2841054T (enExample) |
| MX (2) | MX387891B (enExample) |
| MY (3) | MY210484A (enExample) |
| NZ (1) | NZ630335A (enExample) |
| PH (2) | PH12014502379B1 (enExample) |
| PL (1) | PL2841054T5 (enExample) |
| PT (1) | PT2841054T (enExample) |
| SG (3) | SG11201406451SA (enExample) |
| SI (1) | SI2841054T2 (enExample) |
| TW (6) | TW202425992A (enExample) |
| UA (1) | UA115444C2 (enExample) |
| WO (1) | WO2013162048A1 (enExample) |
| ZA (1) | ZA201407335B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| CN105461703B (zh) * | 2014-12-29 | 2019-05-17 | 深圳市泛谷药业股份有限公司 | 一种brexpiprazole的制备方法 |
| JP6513461B2 (ja) * | 2015-04-14 | 2019-05-15 | 帝國製薬株式会社 | ブレクスピプラゾールの経皮吸収製剤 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| US11235976B2 (en) * | 2017-01-26 | 2022-02-01 | Sichuan Yingrui Pharmaceutical Technology Company | Nanocarbon-iron composite system as well as composition, preparation method and use thereof |
| US10987303B2 (en) | 2018-05-02 | 2021-04-27 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| WO2020089942A2 (en) * | 2018-11-02 | 2020-05-07 | Amaterasu Lifesciences Llp | A liquid injectable composition |
| WO2021199076A1 (en) * | 2020-03-30 | 2021-10-07 | Cipla Limited | Injectable aripiprazole formulation |
| KR20220161402A (ko) * | 2020-04-01 | 2022-12-06 | 오츠카 세이야쿠 가부시키가이샤 | 아리피프라졸 치료의 용량 개시 방법 |
| US20230372317A1 (en) * | 2020-10-27 | 2023-11-23 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US11910794B2 (en) | 2021-03-08 | 2024-02-27 | Monsanto Technology Llc | Solutions and methods for long-term pollen storage |
| WO2023067664A1 (ja) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | ベンゾチオフェン化合物の新規結晶形及びその製造方法 |
| WO2023240971A1 (zh) * | 2022-06-16 | 2023-12-21 | 江苏慧聚药业股份有限公司 | 药物组合物及依匹哌唑口溶膜 |
| CN115969785A (zh) * | 2022-12-30 | 2023-04-18 | 辰欣药业股份有限公司 | 一种阿立哌唑注射剂及其制备方法 |
| CA3197997A1 (en) * | 2023-03-17 | 2025-01-23 | Otsuka Pharma Co Ltd | METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE |
| CN120957722A (zh) | 2023-04-26 | 2025-11-14 | 大塚制药株式会社 | 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动 |
| WO2025051281A1 (zh) * | 2023-09-08 | 2025-03-13 | 广州玻思韬控释药业有限公司 | 注射用依匹哌唑凝胶 |
| WO2025183016A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864100A (en) * | 1957-04-09 | 1961-03-29 | Pfizer & Co C | Therapeutic pencillin compositions and the preparation thereof |
| JPS5913714A (ja) | 1982-07-13 | 1984-01-24 | Taito Pfizer Kk | 外用消炎鎮痛剤 |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| JP4012994B2 (ja) | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| PE20030445A1 (es) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| JP2003171264A (ja) * | 2001-12-07 | 2003-06-17 | Taiyo Yakuhin Kogyo Kk | マイクロカプセル及びその製造方法 |
| JP2003238393A (ja) | 2002-02-15 | 2003-08-27 | Otsuka Pharmaceut Co Ltd | 施錠性が改善された錠剤及びその製造方法 |
| RU2342931C2 (ru) | 2002-08-20 | 2009-01-10 | Бристол-Маерс Сквибб Компани | Состав на основе комплекса арипипразола |
| AU2003295235B2 (en) | 2002-12-27 | 2008-06-19 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| ATE308524T1 (de) | 2003-01-09 | 2005-11-15 | Otsuka Pharma Co Ltd | Verfahren zur herstellung von aripiprazole |
| WO2004064752A2 (en) | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| US20070110784A1 (en) * | 2003-05-02 | 2007-05-17 | Rimon Therapeutics Ltd. | Thermally reversible implant |
| CN102166359A (zh) | 2003-05-23 | 2011-08-31 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| CA2543242C (en) * | 2003-10-23 | 2015-04-14 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| WO2005044242A1 (en) | 2003-10-27 | 2005-05-19 | Dow Corning Corporation | Preparations for topical application and methods of delivering an active agent to a substrate |
| AU2005206143B2 (en) | 2004-01-12 | 2010-12-16 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| JP2006219380A (ja) * | 2005-02-08 | 2006-08-24 | Minofuaagen Seiyaku:Kk | グリチルリチン皮下注射製剤 |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| US20070148100A1 (en) | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| WO2007061896A1 (en) | 2005-11-17 | 2007-05-31 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
| JP4373983B2 (ja) | 2006-01-27 | 2009-11-25 | 三菱電機インフォメーションシステムズ株式会社 | 流通経路管理装置及び流通経路管理プログラム |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| AR063120A1 (es) * | 2006-10-05 | 2008-12-30 | Panacea Biotec Ltd | Composiciones inyectables de deposito y proceso para prepararlas |
| JP4540700B2 (ja) | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| WO2008090632A1 (en) | 2007-01-26 | 2008-07-31 | Otsuka Pharmaceutical Co., Ltd. | Marker for detecting the proposed efficacy of treatment |
| AU2008268222B2 (en) | 2007-06-25 | 2013-12-12 | Otsuka Pharmaceutical Co., Ltd. | Microspheres having core/shell structure |
| MX2010001311A (es) * | 2007-07-31 | 2010-04-21 | Otsuka Pharma Co Ltd | Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada. |
| US20090258850A1 (en) * | 2007-08-21 | 2009-10-15 | Frincke James M | Stabilized therapeutic compositions and formulations |
| JP2011136906A (ja) | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| JP2009286740A (ja) | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
| TR200809200A1 (tr) * | 2008-12-01 | 2009-12-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Meloksikam içeren farmasötik formülasyonlar |
| EP3167875A1 (en) | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |
| CA2773253A1 (en) | 2009-09-11 | 2011-03-17 | Shin-Ichi Niwa | Therapeutic agent for chronic pain comprising aripiprazole |
| NZ603076A (en) | 2010-08-24 | 2014-12-24 | Otsuka Pharma Co Ltd | Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative |
| EP2629775A4 (en) * | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | INJECTABLE FORMULATION WITH DELAYED RELEASE |
| AR083884A1 (es) | 2010-11-16 | 2013-03-27 | Otsuka Pharma Co Ltd | Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa |
| JP2012121850A (ja) | 2010-12-09 | 2012-06-28 | Otsuka Pharmaceut Co Ltd | アリピプラゾールの経口速溶性組成物 |
| HUE055836T2 (hu) | 2011-01-24 | 2021-12-28 | Otsuka Pharma Co Ltd | Aripiprazolt hatóanyagként tartalmazó pogácsakészítményt tartalmazó orvostechnikai eszköz és aripiprazolt hatóanyagként tartalmazó pogácsakészítmény |
| JOP20120083B1 (ar) | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
| JP2012232958A (ja) † | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| JO3410B1 (ar) | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | تركيبة أريبيبرازول مجفف بالتبريد |
| JP6034377B2 (ja) * | 2011-06-27 | 2016-11-30 | シャンハイ チョンシ ファーマシューティカル コーポレイション | アリピプラゾール医薬製剤及びその調製方法 |
| TW201309651A (zh) | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| CA2843241C (en) | 2011-07-28 | 2021-01-26 | Otsuka Pharmaceutical Co., Ltd. | Method for producing benzo[b]thiophene compound |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI679977B (zh) | 2011-10-19 | 2019-12-21 | 大塚製藥股份有限公司 | 口服溶液 |
| TW201332572A (zh) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| JP2013139441A (ja) | 2011-12-28 | 2013-07-18 | Otsuka Pharmaceut Co Ltd | マイクロスフェア |
| TW201343201A (zh) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | 持續釋放型口服固體製劑 |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
-
2012
- 2012-04-23 JO JOP/2020/0109A patent/JOP20200109A1/ar unknown
-
2013
- 2013-04-22 AR ARP130101321A patent/AR090776A1/es not_active Application Discontinuation
- 2013-04-23 MY MYPI2023004225A patent/MY210484A/en unknown
- 2013-04-23 ES ES13728542T patent/ES2743706T5/es active Active
- 2013-04-23 MY MYPI2018001894A patent/MY198007A/en unknown
- 2013-04-23 MX MX2018010879A patent/MX387891B/es unknown
- 2013-04-23 AU AU2013253374A patent/AU2013253374B2/en active Active
- 2013-04-23 SI SI201331550T patent/SI2841054T2/sl unknown
- 2013-04-23 UA UAA201411954A patent/UA115444C2/uk unknown
- 2013-04-23 TW TW112130297A patent/TW202425992A/zh unknown
- 2013-04-23 JP JP2015506529A patent/JP6234996B2/ja active Active
- 2013-04-23 SG SG11201406451SA patent/SG11201406451SA/en unknown
- 2013-04-23 WO PCT/JP2013/062683 patent/WO2013162048A1/en not_active Ceased
- 2013-04-23 SG SG10201913425VA patent/SG10201913425VA/en unknown
- 2013-04-23 DK DK13728542.5T patent/DK2841054T4/da active
- 2013-04-23 CN CN201380021440.9A patent/CN104470499B/zh active Active
- 2013-04-23 US US14/396,380 patent/US20150093442A1/en not_active Abandoned
- 2013-04-23 MY MYPI2014002932A patent/MY178573A/en unknown
- 2013-04-23 HU HUE13728542A patent/HUE045979T2/hu unknown
- 2013-04-23 CN CN201810143716.5A patent/CN108186556B/zh active Active
- 2013-04-23 BR BR112014026307-8A patent/BR112014026307B1/pt active IP Right Grant
- 2013-04-23 TW TW113144877A patent/TW202535396A/zh unknown
- 2013-04-23 LT LTEP13728542.5T patent/LT2841054T/lt unknown
- 2013-04-23 PT PT13728542T patent/PT2841054T/pt unknown
- 2013-04-23 TW TW109130917A patent/TW202126303A/zh unknown
- 2013-04-23 TW TW102114410A patent/TWI637752B/zh active
- 2013-04-23 KR KR1020147032714A patent/KR102138852B1/ko active Active
- 2013-04-23 TW TW107109282A patent/TWI713826B/zh active
- 2013-04-23 HR HRP20191366TT patent/HRP20191366T4/hr unknown
- 2013-04-23 EA EA201491685A patent/EA026619B1/ru not_active IP Right Cessation
- 2013-04-23 EP EP19169193.0A patent/EP3539534A1/en active Pending
- 2013-04-23 JO JOP/2013/0116A patent/JO3632B1/ar active
- 2013-04-23 KR KR1020217029406A patent/KR20210116702A/ko not_active Ceased
- 2013-04-23 CN CN202210169142.5A patent/CN114344259B/zh active Active
- 2013-04-23 PL PL13728542.5T patent/PL2841054T5/pl unknown
- 2013-04-23 NZ NZ630335A patent/NZ630335A/en unknown
- 2013-04-23 CA CA3120297A patent/CA3120297A1/en active Pending
- 2013-04-23 SG SG10201608753UA patent/SG10201608753UA/en unknown
- 2013-04-23 CA CA2869889A patent/CA2869889C/en active Active
- 2013-04-23 TW TW111116460A patent/TW202313036A/zh unknown
- 2013-04-23 MX MX2014012811A patent/MX359241B/es active IP Right Grant
- 2013-04-23 KR KR1020207015451A patent/KR102498075B1/ko active Active
- 2013-04-23 KR KR1020247015029A patent/KR20240068788A/ko not_active Ceased
- 2013-04-23 EP EP13728542.5A patent/EP2841054B2/en active Active
-
2014
- 2014-10-09 ZA ZA2014/07335A patent/ZA201407335B/en unknown
- 2014-10-23 IL IL235299A patent/IL235299B/en active IP Right Grant
- 2014-10-23 PH PH12014502379A patent/PH12014502379B1/en unknown
- 2014-11-21 CO CO14256422A patent/CO7151500A2/es unknown
-
2017
- 2017-09-11 US US15/701,202 patent/US20180055941A1/en not_active Abandoned
- 2017-09-14 AU AU2017228608A patent/AU2017228608C1/en active Active
- 2017-10-25 JP JP2017206658A patent/JP6470378B2/ja active Active
-
2018
- 2018-10-10 US US16/156,958 patent/US10517951B2/en active Active
-
2019
- 2019-01-07 AU AU2019200060A patent/AU2019200060A1/en not_active Abandoned
- 2019-01-16 JP JP2019005031A patent/JP2019070028A/ja active Pending
- 2019-03-07 PH PH12019500498A patent/PH12019500498A1/en unknown
- 2019-07-17 US US16/514,973 patent/US20190336607A1/en not_active Abandoned
- 2019-08-28 CY CY20191100912T patent/CY1122252T1/el unknown
-
2020
- 2020-02-07 US US16/785,268 patent/US20200179517A1/en not_active Abandoned
- 2020-06-24 AU AU2020204200A patent/AU2020204200B2/en active Active
- 2020-10-14 JP JP2020172902A patent/JP2021008512A/ja active Pending
- 2020-12-01 US US17/108,939 patent/US11097007B2/en active Active
-
2021
- 2021-08-04 US US17/444,469 patent/US11638757B2/en active Active
-
2022
- 2022-01-14 JP JP2022004098A patent/JP7293412B2/ja active Active
- 2022-09-27 AU AU2022241491A patent/AU2022241491B2/en active Active
- 2022-12-30 US US18/148,860 patent/US12016927B2/en active Active
-
2023
- 2023-06-06 JP JP2023092924A patent/JP7612758B2/ja active Active
-
2024
- 2024-05-13 US US18/662,049 patent/US20250121065A1/en active Pending
- 2024-12-24 JP JP2024226861A patent/JP2025041805A/ja active Pending
-
2025
- 2025-01-13 AU AU2025200229A patent/AU2025200229A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| JP2015514751A5 (enExample) | ||
| JP2018048179A5 (enExample) | ||
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| SI2648520T1 (en) | Formulation of dexmedetomidine pre-mixtures | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| PH12015502290A1 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| JP2014129360A5 (enExample) | ||
| HRP20210980T1 (hr) | Stabilna bez konzervansa midrijatska i protuupalna otopina za injekciju | |
| Agrawal et al. | Formulation development and evaluation of in situ nasal gel of poorly water soluble drug using mixed solvency concept | |
| JP2017525671A5 (enExample) | ||
| HRP20190841T4 (hr) | Injektabilna formulacija | |
| JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
| RU2015100905A (ru) | Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат и тиотропия бромид, а также способ его изготовления | |
| RU2014148544A (ru) | Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| CL2016001148A1 (es) | Sistema multiparticulado para la administración oral de drogas, que comprende partículas de microgel que contienen un ingrediente farmacéutico activo, donde las partículas de microgel están dispersas en una composición líquida no acuosa proceso para prepararlo cápsulas que lo comprenden. | |
| CN106924172A (zh) | 一种石杉碱甲溶致液晶制剂及其制备方法 | |
| HRP20140215T1 (hr) | Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika | |
| BR102013032405A2 (pt) | Composição farmacêutica na forma de uma suspensão oral compreendendo uma fração de flavonoide e uma goma de xantano | |
| CN103284949B (zh) | 一种吉他霉素纳米乳抗菌药物及其制备方法 | |
| HRP20190642T1 (hr) | Pripravci aripiprazolskog predlijeka | |
| AR126033A2 (es) | Preparación inyectable, y jeringa prellenada que contiene la preparación inyectable | |
| MX380536B (es) | Composicion y metodo para tratar la enfermedad de chagas. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf |